Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Affimed $100 million at-the-market offering
The shares are listed on the Nasdaq Global Market
Cryoport $403 million notes offering and concurrent $249 million stock offering
The company issued 0.75% convertible senior notes due 2026 and sold shares in a registered direct offering
Aligos Therapeutics $75 million at-the-market offering
The company issued common stock in the SEC-registered at-the-market offering
Option Care Health $500 million notes offering
The company issued high-yield senior notes due 2029 in the Rule 144A / Regulation S offering
IVERIC bio $173.4 million stock offering
We advised the underwriters on the SEC-registered equity offering
MicroTech Medical HK$1.82 billion IPO
We advised MicroTech Medical on its IPO and HKEX listing
Abbisko HK$1.7 billion IPO
We advised Abbisko on its IPO and HKEX listing
PHC Holdings ¥82.6 billion IPO
We advised the international managers in connection with the IPO and TSE listing
Supernus Pharmaceuticals $450 million acquisition of Adamas Pharmaceuticals
We are advising Lazard as financial adviser to Adamas
Securities litigation victory for Synergy Pharmaceuticals officers and directors
We secured a total victory for the clients, with all claims against them dismissed